NCT02530489View on ClinicalTrials.gov

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 4, 2016

Primary Completion Date

May 23, 2025

Study Completion Date

May 23, 2025

Conditions

Breast AdenocarcinomaInvasive Breast CarcinomaTriple-Negative Breast Carcinoma

Interventions

DRUG

Atezolizumab

Given IV

DRUG

Nab-paclitaxel

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT02530489 - Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter